Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales ...

Eli Lilly said its tirzepatide franchise had another stellar quarter.

Surging consumer demand for blockbuster weight-loss drugs helped offset their declining prices.

By Christy Santhosh and Mrinalika Roy April 30 (Reuters) - Eli Lilly hiked its full-year profit and revenue forecasts on ...

Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for ...

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO) now ...

After just a few weeks on the market, thousands are already on Foundayo, Eli Lilly's oral weight loss pill. The drugmaker is ...

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.

The Indianapolis-based drugmaker reported profit of $7.4 billion for the first quarter, up from $2.8 billion in the same period a year earlier.

Eli Lilly (LLY) stock jumps as the company raised its full-year outlook alongside better-than-expected Q1 2026 financials ...

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...